Compare MRKR & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | SNAL |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 26.6M |
| IPO Year | 2010 | 2022 |
| Metric | MRKR | SNAL |
|---|---|---|
| Price | $1.21 | $5.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 527.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.61 | ★ 120.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,225,622.00 |
| Revenue This Year | N/A | $15.53 |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.34 |
| 52 Week High | $2.46 | $5.92 |
| Indicator | MRKR | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 70.54 |
| Support Level | $1.17 | $0.65 |
| Resistance Level | $1.52 | $5.92 |
| Average True Range (ATR) | 0.07 | 0.62 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 1.76 | 60.28 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.